Objective  To investigate the clinical features, therapeutic outcomes, and prognostic factors of pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.

  Methods  Clinical data of 14 cases of pulmonary MALT lymphoma from the West China Hospital over an 11-year period were enrolled in the current study, and the clinical records of these patients were analyzed.

  Results  The age of onset of the 14 MALT lymphoma patients ranged from 33 to 73 years old. The patients had a mean onset age of 52.36 ± 13.08 years. Their peak age was between 40 and 60 years old in the cases where the number of the patients with peak age amounted to 50% of the total. The patients had male to female ratio of 1:1, and the incidence rate of stage-Ⅰand -Ⅱ MALT lymphoma reached 92.86% (13/14). The symptom of B-cell lymphoma attained 50% (7/14), and the extra-nodal involvement reached 64.29% (9/14) in the patients. The treatment included surgery, combination chemotherapy, and interferon therapy. The median follow-up time of the patients was 37.86 ± 19.52 months, the overall survival rate of all patients was 100% (14/14), and the progression free survival rate was 57.14% (8/14). The number of extra-nodal involvement was ≥ 2, and the clinical stage ≥ Ⅲ. The elevated LDH and IgM levels were the poor prognostic factors.

  Conclusion  Pulmonary MALT lymphoma had non-specific clinical situation and diverse radiologic manifestations. Histo-pathologic examination was the gold standard for the diagnosis. Combination chemotherapy, including rituximab, was the standard treatment.